European Leukemia Trial Registry
Trial: AMLSG 11-08

More Details
Title Phase Ib/IIa Study For the Evaluation of Dasatinib Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML
Scientific Title Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML
Short Title AMLSG 11-08
Trialgroup AMLSG Ulm
Type of Trial multicentric, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Closed
Start of Recruitment 03.09.2009
Leader Döhner, Prof. Dr. med., Hartmut
Contactperson

Biometrics
Benner, A.
Tel: +49 (0)6221 422390
Fax: +49 (0)6221 422397
Email: benner@dkfz-heidelber.de
Homepage: www.dkfz.de

Study Centre
Weber, Daniela
Tel: +49 (0)731 50056072
Fax: +49 (0)731 50045905
Email: aml.sekretariat@uniklinik-ulm.de

Shortprotocol Shortprotocol
Diagnostics

Molecular Genetics
Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm
Labor für Leukämieforschung der Medizinischen Hochschule Hannover

created 06.10.2009 Roswitha Kotthoff
changed 24.07.2017 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org